CDK4 and glioma: Qi et al.21 demonstrated that overexpression of PIKE-A or CDK4 alone in the TP53/PTEN double knockout GBM mouse model has longer latency of glioma onset and survival relative to co-express PIKE-A and CDK4 (ref. 21).